IO Biotech, Inc. · OTC:IOBTQ
IO Biotech — Investor Presentation (January 2024)
31 slides from IO Biotech's investor presentation, Jan 8, 2024
Slide 1: Break Boundaries. Ignite Change. Corporate Presentation January 2024
Break Boundaries. Ignite Change. Nasdaq: IOBT Corporate Presentation January 2024 Exhibit 99.1
Slide 2: Disclaimer | Forward Looking Statements
DISCLAIMER | Forward Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our business p
Slide 3: Highlights
Indications: Melanoma SCCHN NSCLC 3 T-win cancer vaccine technology platform 1 3 Pipeline programs 17 Patent Families Focused on improving clinical effect without adding systemic toxicity 50% 80% * Results from phase 1/2 MM1636 Melanoma 25.5 Months mPFS* Providing rapid and durable responses HIGHLIG
Slide 4: Content: Patient and Market Perspective
PATIENT AND MARKET PERSPECTIVE 1 OUR UNIQUE VALUE PROPOSITION 2 OUR PIPELINE AND THE SCIENCE BEHIND IT 3 GROWTH STRATEGY AND OUTLOOK 4 THE IO BIOTECH TEAM 5 CONTENT
Slide 5: Patient Focus: Improving outcomes without adding systemic toxicity
PATIENT FOCUS | Improving patient outcomes without adding systemic toxicity on both advanced and earlier stages of cancer * IOBT is also present in two other indications: Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Non-Small Cell Lung Cancer Treatment (NSCLC) ** Results from phase 1/2 M
Slide 6: Market: Unmet need in large and growing indications
MARKET | IO Biotech aims to address the unmet need in 3 large and growing indications Squamous Cell Carcinoma of the Head and Neck* (SCCHN) Non-Small Cell Lung Cancer Treatment** (NSCLC) Melanoma New cases, worldwide Deaths, worldwide New cases, worldwide Deaths, worldwide New cases, worldwide Death
Slide 7: Market: Expected growth in global cancer drug sales
2028 2022 16 14 12 10 8 6 4 2 +11% 2028 2022 2028 2022 Forecast global Melanoma Drug Sales in USD billions Forecast global SCCHN Drug Sales in USD billions Forecast global NSCLC Drug Sales in USD billions 0.0 4.0 5.0 4.5 3.5 3.0 2.5 2.0 1.5 1.0 0.5 +8% 0 90 80 70 60 50 40 30 4.3 9.0 5.4 3.3 20 10 +1
Slide 8: Market: Solid tumors often detected at advanced stages
MARKET | Solid tumors are often detected at advanced stages, or progressing quickly to advanced stage, increasing the mortality rate ~325,000 New cases in 2020, worldwide ~57,000 Deaths in 2020, worldwide ~744,000 New cases in 2020, worldwide ~364,000 Deaths in 2020, worldwide Melanoma Non-Small Cel
Slide 9: Market: Worldwide cancer threats by region
MARKET | Melanoma, SCCHN, and NSCLC are worldwide cancer threats, but especially present in Europe, North America and Oceania 16,1 Northern America Oceania Europe 9,0 Melanoma SCCHN NSCLC 27,71 11,4 11,0 25,0 30,1 11,2 20,4 Asia 0,4 8,1 19,5 Melanoma, SCCHN, and NSCLC incidence in 2020, age standard
Slide 10: Content: Our Unique Value Proposition
PATIENT AND MARKET PERSPECTIVE 1 OUR UNIQUE VALUE PROPOSITION 2 OUR PIPELINE AND THE SCIENCE BEHIND IT 3 GROWTH STRATEGY AND OUTLOOK 4 THE IO BIOTECH TEAM 5 CONTENT
Slide 11: Clinical proof of concept and value proposition
Clinical POC Enhanced activity outcomes when administered in combination with anti PD-1 therapy high ORR of 80%, with 50% of patients reaching a CR Duration of response demonstrated rapid and durable responses No added systemic toxicity Favorable safety & tolerability Safety profile of IO102-IO103 c
Slide 12: Unique Value Proposition: Physician feedback
UNIQUE VALUE PROPOSITION | Preliminary physician feedback highlights from market research the potential of IO Biotech’s vaccine IO102-IO103 The mOS is the most impressive data presented - the 16 months improvement is excellent – FR KOL (if) the ORR is superior to ipi + nivo, this product will become
Slide 13: Unique Value Proposition: Addressing unmet needs vs current therapies
IO Biotech is developing a cancer vaccine aiming to improve patient outcomes, without adding systemic toxicity, focusing on efficacy, durability, safety, and tolerability UNIQUE VALUE PROPOSITION | IO Biotech aims to address the unmet needs of the patients vis-à-vis current therapies Parameter Stand
Slide 14: Content: Our Pipeline and the Science Behind It
PATIENT AND MARKET PERSPECTIVE 1 OUR UNIQUE VALUE PROPOSITION 2 OUR PIPELINE AND THE SCIENCE BEHIND IT 3 GROWTH STRATEGY AND OUTLOOK 4 THE IO BIOTECH TEAM 5 CONTENT
Slide 15: Technology Platform: T-Win cancer vaccines dual mechanism of action
TECHNOLOGY PLATFORM | T-Win® cancer vaccines have a dual mechanism of action, targeting both tumor cells and immuno-suppressive cells in the TME T cells attack both tumor cells and target-expressing immuno-suppressive cells (e.g., IDO1, PDL1) The modulated and inflamed TME becomes immune permissive,
Slide 16: Pipeline
IA 3Q-2024 Product candidates Line of therapy/ indication Pre-clinical Phase 1 Phase 2 Phase 3 Takeaways IO102-IO103 Targets: IDO, PD-L1 First Line Advanced Melanoma* Phase 3 pivotal trial fully enrolled; outcome of interim analysis (IA) expected 3Q24. Potential accelerated approval in 2025 if suppo
Slide 17: Clinical Trials: Totality of clinical data for IO102-IO103
CLINICAL TRIALS | The totality of clinical data for IO102-IO103 is encouraging Ph1/2 in melanoma (MM1636) with encouraging results, driving continued clinical development à Ph3 in first-line advanced melanoma (IOB-013/KN-D18) Ongoing Ph2 in solid tumors basket (IOB-022/KN-D38) with encouraging preli
Slide 18: Clinical Trials: Phase 1/2 outcomes published in Nature Medicine
CLINICAL TRIALS | Successful outcomes from phase 1/2 were published in Nature Medicine and drove continued clinical development for 1L melanoma Compelling Data Published in Nature Medicine December 09, 2021 Results showing an attractive safety profile January 2023 Data Cut* as Published in JITC, May
Slide 19: Next Steps: Phase 3 trial design and interim analysis
NEXT STEPS Pre-defined interim analysis of ORR: First 225 patients 12 months post randomization; Outcome of interim analysis expected in 3Q2024; if supportive, BLA submission for accelerated approval MILESTONES IDMC meeting in September 2023 recommended that the trial continue without modifications;
Slide 20: Clinical Trials: Phase 2 Head & Neck and Lung cancer
PRIMARY ENDPOINT ORR SECONDARY/EXPLORATORY ENDPOINTS PFS (RECIST1.1) DoR CR DCR OS Safety CLINICAL TRIALS | Treatments for Head & Neck and Lung cancer are currently in phase 2 with encouraging preliminary data 1:1 IO102-IO103 and Pembrolizumab 200mg q3w NSCLC PD- L1 TPS ≥ 50% SCCHN (HPV +/-) PD- L1
Slide 21: Clinical Trials: NSCLC and SCCHN preliminary analysis
CLINICAL TRIALS | Preliminary analysis shows 5 NSCLC and 3 SCCHN patient partial responses having more than 180 days PFS Cohort A: NSCLC-adenocarcinoma Cohort B: SCCHN NSCLC results (N=18) SCCHN results (N = 6) Encouraging preliminary data reported Best overall response N = 18 ORR (95% CI)* 56% [30.
Slide 22: Clinical Trials: Neo-adjuvant/adjuvant Phase 2 enrolling
CLINICAL TRIALS | Neo-adjuvant/adjuvant treatment for Melanoma and Head & Neck cancer are currently enrolling a phase 2 1:1 IO102-IO103 and Pembrolizumab (200mg q3w) Melanoma Resectable Stage III SCCHN Resectable Stage III/IV N= 15 per cohort Resectable melanoma or SCCHN Candidate for surgical resec
Slide 23: Time to Treatment: Off-the-shelf therapeutic cancer vaccines
TIME TO TREATMENT | IOBT’s off-the-shelf therapeutic cancer vaccines ensure patients can receive treatment without delay* GMP Manufacturing Vaccine production Storage The vaccine is stored at 2-8°C Procurement The vaccine is ordered by the clinic Patient Vaccination The patient receives the vaccine
Slide 24: Content: Growth Strategy and Outlook
PATIENT AND MARKET PERSPECTIVE 1 OUR UNIQUE VALUE PROPOSITION 2 OUR PIPELINE AND THE SCIENCE BEHIND IT 3 GROWTH STRATEGY AND OUTLOOK 4 THE IO BIOTECH TEAM 5 CONTENT
Slide 25: Growth Strategy: Platform built since 2014, potential US launch 2025
IOB-022 – basket trial data GROWTH STRATEGY | Since its foundation in 2014, IO Biotech has built a strong platform and has the potential for US market launch in 2025 Company Founded MM1636@CCIT (IDO and PD-L1 peptides) starts showing impressive data FDA grants BTD designation MM1636 data presented a
Slide 26: Growth Strategy: First mover advantage in melanoma and expansion
GROWTH STRATEGY | The aim is to use our first mover advantage in melanoma and expand into multiple cancer types and earlier settings Building a solid science platform with a unique value proposition Immune-modulating cancer vaccine targeting both the tumor and the immune suppressive cells Significan
Slide 27: Outlook: Clinical milestones supported by cash runway into 4Q2025
OUTLOOK | Important clinical milestones expected in the next two years, supported by $165.5 M* cash runway into 4Q2025 Program Phase Indication Line of therapy IO102-IO103 Targets: IDO, PD-L1 Phase 3 Melanoma First-line advanced IO102–IO103 Phase 2 Basket trials Lung (NSCLC) Head & Neck (SCCHN) Firs
Slide 28: Content: The IO Biotech Team
PATIENT AND MARKET PERSPECTIVE 1 OUR UNIQUE VALUE PROPOSITION 2 OUR PIPELINE AND THE SCIENCE BEHIND IT 3 GROWTH STRATEGY AND OUTLOOK 4 THE IO BIOTECH TEAM 5 CONTENT
Slide 29: The Team: Strong management team
THE TEAM | We have a strong management team with large biopharma and biotech experience Mai-Britt Zocca, Ph.D. Chief Executive Officer Qasim Ahmad, M.D. Chief Medical Officer Amy Sullivan, M.B.A. Chief Financial Officer Eric Faulkner, M.B.A. Chief Technical Officer Devin Smith General Counsel Dan Ma
Slide 30: The Team: Board of Directors and Scientific Advisory Board
Board of Directors THE TEAM | Our management team is supported by the Board of Directors and the Scientific Advisory Board Peter Hirth, Ph.D. Chairman Kathleen Sereda Glaub, M.B.A. Member Christian Elling, Ph.D. Member – Lundbeckfonden Heidi Hunter Member Jack B. Nielsen, M.Sc Member – Vivo Capital
Slide 31: Highlights
Indications: Melanoma SCCHN NSCLC 3 T-win cancer vaccine technology platform 1 3 Pipeline programs 17 Patent Families Focused on improving clinical effect without adding systemic toxicity 50% 80% * Results from phase 1/2 MM1636 Melanoma 25.5 Months mPFS* Providing rapid and durable responses HIGHLIG